midst
epidem
therapeut
candid
unlik
abl
complet
usual
multiyear
clinic
trial
regulatori
approv
process
within
cours
outbreak
appli
bayesian
adapt
patientcent
modelwhich
minim
expect
harm
fals
posit
fals
negativesto
optim
clinic
trial
develop
path
outbreak
epidem
infecti
fatal
bayesianoptim
sampl
size
clinic
trial
lower
optim
statist
signific
level
higher
assum
static
initi
infect
percentag
optim
signific
level
clinic
trial
nonvaccin
antiinfect
therapeut
clinic
trial
vaccin
dynam
rang
correspond
valu
respect
result
illustr
import
adapt
clinic
trial
design
regulatori
approv
process
specif
paramet
stage
epidem
grow
public
concern
outbreak
coronaviru
diseas
signific
effort
undertaken
global
biomed
stakehold
develop
effect
diagnost
vaccin
antivir
drug
medic
devic
therapeut
highli
infecti
deadli
pandem
past
tradit
random
clinic
trial
rct
regulatori
approv
process
often
took
sever
year
us
food
drug
administr
longer
typic
durat
epidem
outbreak
pronker
et
al
recent
fda
respond
action
breakthrough
devic
program
emerg
use
author
eua
author
immedi
effect
guidanc
document
prevent
novel
diagnost
therapeut
lag
behind
urgent
need
popul
paper
propos
adapt
yet
anoth
tool
fda
alreadi
explor
medic
devic
chaudhuri
et
al
therapeut
treat
current
develop
recent
year
bayesian
adapt
rct
protocol
increasingli
use
expedit
clinic
trial
process
potenti
transform
therapi
diseas
high
mortal
rate
berri
current
protocol
mainli
appli
within
oncolog
domain
ispi
breast
cancer
barker
et
al
gbm
agil
glioblastoma
alexand
et
al
studi
use
bayesian
infer
algorithm
greatli
reduc
number
patient
need
assess
therapeut
effect
drug
candid
without
lower
statist
power
final
approv
decis
measur
type
ii
error
rate
result
therapeut
candid
progress
quickli
regulatori
process
reach
patient
faster
lower
cost
sever
diseas
cur
treatment
pancreat
cancer
patient
tend
toler
higher
type
error
accept
ineffect
therapi
exchang
lower
type
ii
error
reject
effect
therapi
well
expedit
approv
potenti
effect
treatment
base
observ
patientcent
bayesian
protocol
propos
isakov
et
al
montazerhodjat
et
al
incorpor
patient
valu
clinic
trial
design
identifi
optim
balanc
possibl
fals
posit
type
error
fals
neg
type
ii
error
sever
diseas
protocol
set
toler
type
error
rate
much
larger
tradit
threshold
lead
higher
rate
approv
expedit
approv
decis
howev
origin
bayesian
adapt
rct
framework
take
account
patient
risk
prefer
address
gap
develop
adapt
version
bayesian
patientcent
model
achiev
optim
balanc
type
type
ii
error
rate
significantli
reduc
number
subject
need
trial
achiev
statist
signific
conclus
key
featur
model
time
evolut
loss
function
bayesian
decis
algorithm
mechan
favor
expedit
approv
diagnost
therapeut
candid
show
earli
posit
effect
sinc
patient
place
lower
valu
delay
approv
effect
diagnost
therapi
natur
subtl
analog
dilemma
case
therapeut
infecti
diseas
cours
epidem
outbreak
approv
effect
therapeut
earli
prevent
futur
infect
death
approv
later
save
fewer
peopl
infect
hand
approv
ineffect
therapeut
earli
april
xu
chaudhuri
xiao
lo
page
right
reserv
prevent
futur
casualti
wors
still
may
prevent
peopl
take
adequ
precaut
infect
sinc
fals
believ
safe
diseas
advent
ineffect
therapi
moreov
cost
type
versu
type
ii
error
differ
therapi
therapi
novel
vaccin
could
trigger
signific
immun
respons
cytokin
storm
much
higher
cost
type
error
medic
devic
air
filtrat
system
design
destroy
virion
intens
ultraviolet
light
therefor
appropri
statist
threshold
approv
depend
specif
therapi
well
circumst
current
burden
diseas
articl
appli
bayesian
adapt
protocol
antiinfect
therapeut
develop
use
loss
function
evolv
cours
epidem
outbreak
achiev
optim
balanc
type
type
ii
error
therapeut
treat
infecti
diseas
identifi
optim
time
reach
approv
decis
base
accumul
clinic
evid
result
show
epidem
infecti
necessari
sampl
size
rct
decreas
toler
type
error
increas
confirm
earlier
intuit
potenti
effect
therapi
known
safe
receiv
expedit
approv
epidem
spread
rapidli
start
point
analysi
susceptibleexposureinfectiveremov
seir
epidem
model
appli
model
outbreak
china
number
recent
studi
yang
et
al
wu
et
al
popul
n
subject
partit
four
distinct
group
suscept
expos
e
infecti
remov
r
time
evolut
epidem
specifi
follow
group
ordinari
differenti
equat
use
convent
proport
suscept
expos
infecti
remov
popul
respect
satisfi
conserv
constraint
paramet
denot
averag
rate
infect
incub
recoveri
respect
denot
mortal
rate
epidem
exampl
expect
infect
subject
die
diseas
time
subject
die
recov
critic
measur
infect
epidem
basic
reproduct
number
defin
seir
model
expect
number
secondari
infect
caus
infect
subject
popul
public
health
measur
quarantin
socialdistanc
vaccin
addit
model
impact
government
nonpharmaceut
intervent
npi
contain
spread
epidem
consid
dynam
transmiss
seir
model
infect
rate
monoton
decreas
time
result
npi
specif
assum
take
sigmoid
function
form
denot
infect
rate
initi
final
stage
epidem
respect
denot
halflif
decay
infect
rate
length
time
window
decay
occur
larger
differ
correspond
signific
reduct
epidem
transmiss
smaller
valu
correspond
speedier
decis
enforc
npi
smaller
valu
correspond
strict
enforc
npi
sinc
decay
rapidli
calibr
valu
base
estim
dynam
transmiss
rate
wuhan
china
decemb
februari
kucharski
et
al
consid
differ
valu
reflect
variabl
time
stringenc
npi
enforc
govern
around
globe
model
signific
variabl
mortal
rate
patient
differ
age
group
extend
basic
model
multigroup
seir
model
popul
partit
five
age
group
use
denot
correspond
type
group
continu
use
total
proport
type
group
dynam
epidem
specifi
modifi
ordinari
differenti
equat
denot
contact
rate
suscept
subject
th
age
group
total
infect
popul
group
contact
rate
measur
rel
group
normal
case
although
mortal
rate
much
higher
senior
popul
onder
et
al
elderli
also
tend
less
frequent
contact
infect
popul
outsid
household
walker
et
al
solv
differenti
equat
multigroup
seir
model
use
solver
matlab
initi
condit
age
group
paramet
denot
proport
initi
infect
popul
ratio
initi
expos
infect
subject
percentag
th
age
group
popul
assum
demograph
contact
rate
mortal
rate
valu
summar
tabl
similar
develop
bayesian
patientcent
decis
model
rct
approv
minim
expect
loss
harm
incur
patient
optim
balanc
loss
type
type
ii
error
loss
refer
financi
cost
afford
patient
rather
loss
patient
valu
ie
much
patient
weigh
rel
harm
infect
death
assign
loss
per
patient
suscept
infect
deceas
sinc
bayesian
decis
threshold
invari
rescal
loss
normal
set
loss
per
patient
infect
assign
loss
per
patient
death
rel
loss
due
suscept
diseas
paramet
valu
assum
summar
tabl
meant
repres
one
reason
valuat
rel
loss
howev
practic
patient
valu
differ
one
patient
group
anoth
especi
given
larg
variabl
mortal
rate
differ
age
group
onder
et
al
report
main
result
optim
sampl
size
statist
signific
tabl
assum
result
provid
supplementari
materi
simul
multigroup
seir
model
time
period
week
durat
epidem
outbreak
let
denot
weekli
subject
enrol
rate
arm
clinic
trial
assum
valu
known
wellestim
initi
time
stay
constant
cours
outbreak
time
bayesian
loss
c
choos
action
defin
approv
approv
effect
defin
cumul
number
infect
patient
time
design
loss
function
penal
type
error
earli
epidem
suscept
term
subtract
base
level
sinc
multigroup
seir
model
predict
subject
infect
epidem
type
error
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
earlier
time
expos
current
suscept
popul
epidem
sinc
fals
believ
safe
diseas
advent
ineffect
therapeut
hand
loss
function
also
penal
correct
approv
decis
made
later
stage
epidem
via
cumul
infect
death
term
correct
delay
approv
decis
therapeut
less
valuabl
sinc
save
fewer
suscept
peopl
infect
death
bayesian
decis
model
consid
null
hypothesi
antiinfect
therapeut
vaccin
clinic
effect
altern
hypothesi
posit
clinic
effect
signaltonois
ratio
use
denot
bayesian
prior
probabl
respect
patientvalu
model
impos
higher
loss
incorrect
approv
earlier
stage
correct
approv
later
stage
epidem
constraint
bayesian
decis
algorithm
yield
sampl
size
statist
signific
threshold
rct
optim
balanc
type
type
ii
error
simul
epidem
outbreak
time
period
week
durat
outbreak
epidem
higher
infect
durat
shorter
put
pressur
reach
time
approv
decis
avoid
numer
instabl
formal
defin
first
time
number
cumul
infect
patient
reach
total
infect
predict
seir
model
assum
agespecif
mortal
rate
level
onder
et
al
world
health
organ
incub
recoveri
period
day
yang
et
al
estim
paramet
challeng
vari
degre
depend
specif
drugind
pair
consider
particular
circumst
epidem
meant
repres
typic
antiinfect
therapeut
midst
grow
epidem
also
assum
take
day
inject
assess
efficaci
therapeut
subject
adopt
optim
scheme
montazerhodjat
et
al
find
optim
type
type
ii
error
rate
nonadapt
bayesian
rct
repres
typic
practic
pharmaceut
industri
optim
upper
bound
model
power
power
isakov
et
al
use
optim
error
rate
stop
criteria
simul
sequenti
decis
process
bayesian
adapt
rct
via
mont
carlo
simul
simul
result
summar
tabl
separ
result
two
distinct
type
therapeuticsnonvaccin
antiinfect
vaccinesbecaus
differ
histor
probabl
success
vaccin
develop
program
estim
po
http
projectalphamitedu
wherea
correspond
figur
nonvaccin
antiinfect
wong
et
al
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
first
analyz
case
infect
remain
constant
time
eg
absenc
effect
npi
fixedsampl
bayesian
rct
nonvaccin
antiinfect
therapeut
increas
row
tabl
optim
sampl
size
experiment
arm
decreas
optim
type
error
rate
drastic
increas
figur
much
higher
tradit
threshold
epidem
spread
across
popul
rapidli
bayesian
rct
model
greater
pressur
expedit
approv
process
much
higher
toler
fals
posit
outcom
bayesian
adapt
rct
therapeut
ineffect
averag
sampl
size
requir
reject
therapeut
much
smaller
nonadapt
version
column
tabl
also
requir
sampl
size
decreas
infect
mean
quartil
yet
alway
achiev
type
error
rate
nonadapt
version
column
adapt
bayesian
decis
model
abl
reject
ineffect
therapeut
rel
small
sampl
size
bound
falseposit
rate
hand
therapeut
effect
increas
averag
sampl
size
requir
bayesian
adapt
rct
decreas
column
tabl
bayesian
adapt
model
place
weight
approv
effect
therapeut
earlier
prevent
futur
infect
epidem
infecti
despit
smaller
sampl
size
model
still
retain
empir
power
valu
column
bayesian
adapt
model
simultan
expedit
approv
effect
therapeut
retain
bound
falseneg
rate
result
illustr
figur
furthermor
proport
initi
infect
popul
decreas
row
tabl
optim
sampl
size
nonadapt
adapt
rct
increas
optim
type
error
rate
decreas
begin
clinic
trial
therapeut
earlier
stage
epidem
outbreak
reduc
need
expedit
approv
process
order
contain
futur
spread
clinician
research
time
evalu
efficaci
therapeut
record
advers
effect
test
larger
number
subject
lead
lower
type
error
rate
final
mortal
rate
increas
level
onder
et
al
world
health
organ
level
sar
world
health
organ
level
mer
world
health
organ
optim
sampl
size
nonadapt
adapt
bayesian
model
decreas
optim
type
error
rate
increas
row
tabl
epidem
lethal
bayesian
adapt
model
requir
fewer
subject
rct
sinc
type
type
ii
error
lead
greater
loss
due
death
infect
higher
death
toll
provid
significantli
incent
bayesian
adapt
framework
approv
therapeut
hope
save
peopl
futur
infect
death
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
one
interest
featur
bayesian
decis
model
optim
type
error
rate
monoton
function
rather
global
minimum
shown
figur
decreas
optim
type
error
rate
increas
intuit
result
defin
loss
type
error
excess
risk
suscept
infect
fraction
popul
remain
uninfect
throughout
epidem
outbreak
small
close
excess
risk
small
compar
benefit
prevent
futur
death
therefor
epidem
infecti
bayesian
decis
model
expedit
approv
decis
also
confirm
intuit
smaller
sampl
size
requir
adapt
trial
diseas
affect
small
fraction
popul
instead
defin
loss
type
error
absolut
risk
suscept
find
optim
type
error
inde
monoton
increas
shown
figur
supplementari
materi
result
dynam
transmiss
model
week
week
summar
tabl
row
find
bayesian
optim
sampl
size
type
error
rate
dynam
transmiss
model
lie
scenario
suggest
time
effect
govern
intervent
protect
subject
infect
allow
time
rct
howev
fatal
sar
mer
row
dynam
transmiss
model
set
higher
optim
type
error
smaller
sampl
size
due
ushap
curv
optim
vs
shown
figur
npi
reduc
certain
threshold
optim
start
increas
highli
fatal
epidem
govern
adopt
npi
protect
suscept
popul
infect
regulatori
prioriti
expedit
potenti
effect
treatment
help
current
patient
sinc
loss
type
error
much
lower
type
ii
error
addit
investig
impact
time
stringenc
npi
enforc
govern
differ
valu
result
summar
tabl
find
optim
type
error
larger
week
week
therefor
govern
adopt
wellenforc
npi
earli
lockdown
wuhan
china
protect
suscept
popul
reduc
loss
associ
type
error
lead
expedit
approv
potenti
effect
therapeut
furthermor
sooner
effect
therapeut
approv
sooner
npi
lift
repeat
analysi
rct
vaccin
use
prior
probabl
effect
vaccin
report
http
projectalphamitedu
simul
result
summar
tabl
overal
observ
pattern
optim
sampl
size
type
error
rate
infect
mortal
proport
initi
infect
howev
sinc
higher
vaccin
bayesian
decis
model
requir
fewer
subject
averag
rct
ascertain
posit
effect
vaccin
compar
case
antiinfect
therapeut
tabl
find
vaccin
receiv
even
expedit
evalu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
assess
robust
model
predict
assum
valu
model
paramet
perform
sensit
analysi
paramet
valu
result
summar
supplementari
materi
natur
consequ
use
patientcent
framework
determin
approv
threshold
cours
fals
positivesand
potenti
greater
number
patient
advers
sideeffectsin
case
burden
diseas
high
fals
posit
address
vigil
postapprov
surveil
regulatori
agenc
greater
requir
drug
devic
compani
provid
patientlevel
data
regul
follow
approv
failur
provid
data
evid
ineffect
therapi
ground
revok
approv
howev
past
experi
show
withdraw
approv
drug
challeng
disrupt
sever
reason
onakpoya
heneghan
aronson
therefor
implement
patientcent
approach
may
requir
creat
new
categori
temporari
approv
crisi
situat
involv
urgent
need
nation
intern
level
similar
fda
eua
program
program
might
involv
provision
approv
candid
therapi
consist
oneor
twoyear
licensedepend
natur
drugind
pairto
market
therapi
prespecifi
patient
popul
offlabel
use
therapi
regular
monitor
data
report
regul
manufactur
andor
patient
physician
licens
period
lo
end
trial
period
one
two
outcom
would
occur
depend
accumul
data
period
urgent
need
licens
expir
b
licens
convert
tradit
regulatori
licens
cours
point
trial
period
regul
termin
licens
data
show
therapeut
ineffect
andor
unsaf
process
may
impos
greater
burden
patient
manufactur
regul
may
still
worthwhil
bring
faster
greater
relief
patient
face
mortal
ill
extrem
suffer
respect
urgentne
program
may
view
middl
ground
standard
clinic
trial
approv
similar
spirit
adapt
design
sophist
clinic
trial
master
protocol
ispi
lungmap
gbmagil
patient
care
clinic
investig
simultan
accomplish
also
center
medicar
medicaid
servic
cm
demonstr
willing
cover
cost
certain
therapeut
evid
still
gener
see
exampl
cm
coverag
evid
program
list
http
addit
econom
incent
may
avail
support
temporari
licens
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
appli
bayesian
adapt
patientcent
model
clinic
trial
therapeut
treat
infecti
diseas
epidem
outbreak
use
simpl
epidemiolog
model
find
optim
sampl
size
clinic
trial
decreas
infect
epidem
measur
basic
reproduct
number
time
optim
type
error
rate
increas
lower
level
initi
infect
increas
number
subject
requir
verifi
therapeut
efficaci
therapeut
investig
higher
level
mortal
increas
optim
sampl
size
result
confirm
intuit
clinic
trial
expedit
higher
fals
posit
rate
toler
epidem
spread
rapidli
popul
higher
mortal
rate
alreadi
infect
sizabl
portion
popul
begin
rct
provid
transpar
patientcent
approach
differ
tradit
statist
framework
antiinfect
context
use
rel
simpl
mathemat
model
epidem
diseas
dynam
estim
societ
loss
outbreak
sophist
epidemiolog
model
easili
incorpor
framework
cost
comput
tractabl
transpar
one
interest
tradeoff
explor
differ
vaccin
antivir
treatment
cure
infect
patient
prevent
vaccin
ultim
solut
success
treatment
diseas
use
repurpos
drug
alreadi
approv
indic
whose
safeti
profil
alreadi
establish
may
even
valuabl
especi
deploy
nearer
term
reduc
grow
fear
panic
among
gener
popul
case
approv
threshold
clearli
reflect
costbenefit
differ
cours
practic
regul
consid
mani
factor
beyond
pvalu
make
decis
howev
process
opaqu
even
industri
insid
role
patient
prefer
unclear
propos
patientcent
approach
provid
systemat
object
adapt
repeat
framework
explicitli
incorpor
patient
prefer
burdenofdiseas
data
therapeut
approv
process
framework
also
fulfil
two
mandat
fda
one
fifth
author
prescript
drug
user
fee
act
pdufa
enhanc
quantit
approach
benefitrisk
assess
new
drug
us
fda
section
st
centuri
cure
act
requir
fda
develop
guidelin
patientfocus
drug
develop
includ
collect
patient
prefer
experi
data
explicitli
incorpor
inform
drug
approv
process
hope
work
shed
insight
improv
current
clinic
trial
process
infecti
diseas
therapeut
contribut
time
develop
effect
treatment
patient
particular
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
valu
basic
reproduct
number
li
et
al
zhao
et
al
loss
per
capita
death
infect
loss
per
capita
infect
loss
per
capita
suscept
without
precaut
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
tabl
simul
result
bayesian
adapt
rct
nonvaccin
antiinfect
therapeut
obtain
mont
carlo
run
assum
denot
basic
reproduct
number
diseas
moral
proport
initi
infect
subject
sampl
size
refer
number
subject
enrol
arm
rct
sd
denot
standard
deviat
iqr
interquartil
rang
median
denot
use
dynam
transmiss
model
halflif
week
window
length
week
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
figur
sensit
optim
sampl
size
arm
nonadapt
bayesian
rct
weekli
subject
enrol
rate
lower
upper
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
figur
sensit
optim
type
error
rate
weekli
subject
enrol
rate
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
figur
sensit
optim
sampl
size
arm
nonadapt
bayesian
rct
signal
nois
ratio
snr
treatment
effect
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
figur
sensit
optim
type
error
rate
signal
nois
ratio
snr
treatment
effect
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
figur
sensit
optim
sampl
size
arm
nonadapt
bayesian
rct
prior
probabl
ineffect
treatment
lower
upper
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
figur
sensit
optim
type
error
rate
prior
probabl
ineffect
treatment
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
figur
sensit
optim
sampl
size
arm
nonadapt
bayesian
rct
time
assess
efficaci
nonvaccin
antiinfect
therapeut
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
figur
sensit
optim
type
error
rate
time
assess
efficaci
antiinfect
therapeut
lower
upper
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
figur
sensit
optim
sampl
size
arm
nonadapt
bayesian
rct
incub
rate
infecti
diseas
upper
lower
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
figur
sensit
optim
type
error
rate
incub
rate
infecti
diseas
lower
upper
end
box
plot
fiveparamet
summari
correspond
baselin
valu
use
analysi
tabl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
tabl
optim
sampl
size
type
error
rate
bayesian
nonadapt
rct
antiinfect
therapeut
basic
reproduct
number
close
denot
diseas
moral
proport
initi
infect
subject
sampl
size
denot
number
subject
enrol
arm
rct
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
april
xu
chaudhuri
xiao
lo
page
right
reserv
altern
definit
realist
epidem
loss
type
error
converg
larg
posit
valu
time
approach
end
epidem
outbreak
howev
end
outbreak
infect
patient
thu
suscept
subject
therefor
loss
type
error
approach
zero
case
excess
risk
suscept
absolut
risk
suscept
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
